Journal of the American Society of Nephrology

Journal

Publication Venue For

  • Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. 2020
  • Authors’ Reply.  31:2228-2229. 2020
  • Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial.  31:2122-2132. 2020
  • Early predictors of arteriovenous fistula maturation: A novel perspective on an enduring problem.  31:1617-1627. 2020
  • Clinical pig kidney xenotransplantation: How close are we?.  31:12-21. 2020
  • Single-cell RNA sequencing identifies candidate renal resident macrophage gene expression signatures across species.  30:767-781. 2019
  • APOL1 kidney risk variants and cardiovascular disease: An individual participant data meta-analysis.  30:2027-2036. 2019
  • Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1.  30:2017-2026. 2019
  • Long-term outcomes of arteriovenous fistulas with unassisted versus assisted maturation: A retrospective national hemodialysis cohort study.  30:2209-2218. 2019
  • Tissue-resident macrophages promote renal cystic disease.  30:1841-1856. 2019
  • Erratum: Prediction of arteriovenous fistula clinical maturation from postoperative ultrasound measurements: Findings from the hemodialysis fistula maturation study (Journal of the American Society of Nephrology (2018) 29 (2735-2744)DOI:10.1681/ASN.2017111225).  31:665. 2018
  • Prediction of arteriovenous fistula clinical maturation from postoperative ultrasound measurements: Findings from the Hemodialysis Fistula Maturation Study.  29:2735-2744. 2018
  • A practical guide for treatment of rapidly progressive ADPKD with tolvaptan.  29:2458-2470. 2018
  • A novel method for rapid bedside measurement of GFR.  29:1609-1613. 2018
  • Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria.  29:1615-1623. 2018
  • Evaluation of potential living kidney donors in the APOL1 era.  29:1079-1081. 2018
  • Fibrotic venous remodeling and nonmaturation of arteriovenous fistulas.  29:1030-1040. 2018
  • Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.  29:620-635. 2018
  • Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery.  29:260-267. 2018
  • New ultrasound techniques promise further advances in AKI and CKD.  28:3452-3460. 2017
  • The clinical and economic effect of vascular access selection in patients initiating hemodialysis with a catheter.  28:3679-3687. 2017
  • Haploinsufficiency of the Transcription Factor Ets-1 Is renoprotective in dahl salt-sensitive rats.  28:3239-3250. 2017
  • Histopathology of veins obtained at hemodialysis arteriovenous fistula creation surgery.  28:3076-3088. 2017
  • Intimal hyperplasia, stenosis, and arteriovenous fistula maturation failure in the hemodialysis fistula maturation study.  28:3005-3013. 2017
  • Effects of intensive BP control in CKD.  28:2812-2823. 2017
  • Quantifying postdonation risk of ESRD in living kidney donors.  28:2749-2755. 2017
  • Long-term endothelin-a receptor antagonism provides robust renal protection in humanized sickle cell disease mice.  28:2443-2458. 2017
  • Cell-Free DNA and active rejection in kidney allografts.  28:2221-2232. 2017
  • Global cardiovascular and renal outcomes of reduced GFR.  28:2167-2179. 2017
  • Sickle cell trait and the risk of ESRD in blacks.  28:2180-2187. 2017
  • Association between soluble klotho and change in kidney function: The health aging and body composition study.  28:1859-1866. 2017
  • Prognostic value of serum biomarkers of autoimmunity for recurrence of IGA nephropathy after kidney transplantation.  28:1943-1950. 2017
  • Novel paradigms of salt and hypertension.  28:1362-1369. 2017
  • A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction.  28:1306-1313. 2017
  • Polyomavirus reactivation and immune responses to kidney-specific self-antigens in transplantation.  28:1314-1325. 2017
  • SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function.  28:981-994. 2017
  • An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria.  28:494-503. 2017
  • BP control and long-term risk of ESRD and mortality.  28:671-677. 2017
  • Association between preoperative vascular function and postoperative arteriovenous fistula development.  27:3788-3795. 2016
  • Cellular and molecular mechanisms of AKI.  27:1288-1299. 2016
  • Sulfenic acid modification of endothelin b receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia.  27:398-404. 2016
  • Heme oxygenase-1 gene polymorphisms-toward precision medicine for AKI.  27:3229-3231. 2016
  • Macula densa nitric oxide synthase 1b protects against salt-sensitive hypertension.  27:2346-2356. 2016
  • Past decline versus current EGFR and subsequent mortality risk.  27:2456-2466. 2016
  • Predicted mutation strength of nontruncating PKD1 mutations AIDS genotype-phenotype correlations in autosomal dominant polycystic kidney disease.  27:2872-2884. 2016
  • Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy.  27:3278-3284. 2016
  • Moving beyond minimization trials in kidney transplantation.  26:2898-2901. 2015
  • Outcomes of elderly patients after predialysis vascular access creation.  26:3133-3140. 2015
  • Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.  26:1290-1302. 2015
  • A national study of outcomes among HIV-infected kidney transplant recipients.  26:2222-2229. 2015
  • Contrasting cholesterol management guidelines for adults with CKD.  26:1173-1180. 2015
  • Current understanding of the role of complement in IgA nephropathy.  26:1503-1512. 2015
  • Heme oxygenase-1 regulates myeloid cell trafficking in AKI.  26:2139-2151. 2015
  • Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials.  26:160-172. 2015
  • Lack of association of the APOL1 G3 haplotype in African Americans with ESRD.  26:1021-1025. 2015
  • Phenotype-Genotype correlations and estimated carrier frequencies of primary hyperoxaluria.  26:2559-2570. 2015
  • Reassessing medical risk in living kidney donors.  26:1017-1019. 2015
  • Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.  26:133-147. 2015
  • The furosemide stress test and predicting AKI outcomes.  26:1762-1764. 2015
  • Through a glass darkly: Seeking clarity in preventing late kidney transplant failure.  26:20-29. 2015
  • Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy.  26:1195-1204. 2015
  • Characterization of renal toxicity in mice administered the marine biotoxin domoic acid.  25:1187-1197. 2014
  • The transcription factor E26 transformation-specific sequence-1 mediates neointima formation in arteriovenous fistula.  25:475-487. 2014
  • CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.  25:1760-1773. 2014
  • Cytomegalovirus and anemia: Not just for transplant anymore.  25:1613-1615. 2014
  • Fabry disease: Dose matters.  25:653-655. 2014
  • Lupus nephritis susceptibility loci in women with systemic lupus erythematosus.  25:2859-2870. 2014
  • Patient- And Provider-Reported Information about Transplantation and Subsequent Waitlisting.  25:2871-2877. 2014
  • Quality of life and outcomes in African Americans with CKD.  25:1849-1855. 2014
  • Sphingosine-1-phosphate evokes unique segment-specific vasoconstriction of the renal microvasculature.  25:1774-1785. 2014
  • ABIN1 dysfunction as a genetic basis for lupus nephritis.  24:1743-1754. 2013
  • Cardiovascular risk factors in CKD associate with both ESRD and mortality.  24:1159-1165. 2013
  • Imatinib: Novel treatment of immune-mediated kidney injury.  24:694-701. 2013
  • Proximal tubule proliferation is insufficient to induce rapid cyst formation after cilia disruption.  24:456-464. 2013
  • Evidence-based cardiology in hemodialysis patients.  24:1934-1943. 2013
  • Mechanisms of light chain injury along the tubular nephron.  23:1777-1781. 2012
  • Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.  23:1579-1587. 2012
  • Development of a model of early-onset IgA nephropathy.  23:1364-1374. 2012
  • Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement.  23:1161-1171. 2012
  • Induction of IgA deposits and glomerulonephritis by IgA rheumatoid factor.  23:371-373. 2012
  • ETA activation mediates angiotensin II-induced infiltration of renal cortical T cells.  22:2187-2192. 2011
  • APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.  22:1991-1996. 2011
  • The pathophysiology of IgA nephropathy.  22:1795-1803. 2011
  • Albuminuria and racial disparities in the risk for ESRD.  22:1721-1728. 2011
  • Sepsis and acute kidney injury.  22:999-1006. 2011
  • Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis.  22:839-848. 2011
  • Use of aspirin associates with longer primary patency of hemodialysis grafts.  22:773-781. 2011
  • Medicare reimbursement policies and hemodialysis vascular access outcomes: A need for change.  22:426-430. 2011
  • Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.  22:579-585. 2011
  • Low socioeconomic status associates with higher serum phosphate irrespective of race.  21:1953-1960. 2010
  • Immunoglobulin light chains activate tubular epithelial cells through redox signaling.  21:1165-1173. 2010
  • Normal ciliogenesis requires synergy between the cystic kidney disease genes MKS-3 and NPHP-4.  21:782-793. 2010
  • Heme oxygenase-1 inhibits renal tubular macroautophagy in acute kidney injury.  21:1702-1712. 2010
  • Cystin localizes to primary cilia via membrane microdomains and a targeting motif.  20:2570-2580. 2009
  • TβRI independently activates Smad- and CD2AP-dependent pathways in podocytes.  20:2127-2137. 2009
  • Ferritin prevents calcification and osteoblastic differentiation of vascular smooth muscle cells.  20:1254-1263. 2009
  • Plasma gelsolin and circulating actin correlate with hemodialysis mortality.  20:1140-1148. 2009
  • Kidney function influences warfarin responsiveness and hemorrhagic Complications.  20:912-921. 2009
  • Phosphorus binders and survival on hemodialysis.  20:388-396. 2009
  • C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts.  20:197-204. 2009
  • Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.  20:1103-1112. 2009
  • Toll-like receptor 9 affects severity of IgA nephropathy.  19:2384-2395. 2008
  • Donor ethnicity influences outcomes following deceased-donor kidney transplantation in black recipients.  19:2011-2019. 2008
  • Oscillating cortical thick ascending limb cells at the juxtaglomerular apparatus.  19:1940-1946. 2008
  • Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis.  19:1681-1691. 2008
  • Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis.  19:1629-1633. 2008
  • Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. Con..  19:1632-1633. 2008
  • Impact of activated vitamin D and race on survival among hemodialysis patients.  19:1379-1388. 2008
  • Urinary proteomics in diabetes and CKD.  19:1283-1290. 2008
  • Standard versus high-dose CVVHDF for ICU-related acute renal failure.  19:1233-1238. 2008
  • Systolic dysfunction portends increased mortality among those waiting for renal transplant.  19:1190-1196. 2008
  • Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.  19:1008-1014. 2008
  • Efficacy and safety of renal tubule cell therapy for acute renal failure.  19:1034-1040. 2008
  • Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.  19:615-623. 2008
  • Obesity impacts access to kidney transplantation.  19:349-355. 2008
  • Age affects outcomes in chronic kidney disease.  18:2758-2765. 2007
  • Antiproteinuric therapy and fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β.  18:2609-2617. 2007
  • Improving outcomes from acute kidney injury.  18:1992-1994. 2007
  • Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula.  18:1936-1941. 2007
  • Opening Pandora's box in the tight junction.  18:1624-1625. 2007
  • Enzyme replacement therapy and fabry kidney disease: Quo vadis?.  18:1368-1370. 2007
  • Role of primary cilia in the pathogenesis of polycystic kidney disease.  18:1381-1388. 2007
  • Advances in urinary proteome analysis and biomarker discovery.  18:1057-1071. 2007
  • Immunoglobulin light chains generate hydrogen peroxide.  18:1239-1245. 2007
  • Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study.  18:1344-1352. 2007
  • EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.  18:131-142. 2007
  • Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.  18:143-154. 2007
  • Uric acid: An old dog with new tricks?.  17:1767-1768. 2006
  • Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.  17:1710-1715. 2006
  • Serum uric acid: A risk factor and a target for treatment?.  17. 2006
  • Mortality risk stratification in chronic kidney disease: One size for all ages?.  17:846-853. 2006
  • Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I).  17:3204-3212. 2006
  • Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.  16:2205-2215. 2005
  • Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse.  16:905-916. 2005
  • Association of achieved dialysis dose with mortality in the hemodialysis study: An example of "dose-targeting bias".  16:3371-3380. 2005
  • Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: Role of p53 and Bcl-2-related family proteins.  16:2615-2625. 2005
  • IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease.  16:3651-3660. 2005
  • Renal sodium handling: The role of the epithelial sodium channel.  16:3151-3153. 2005
  • Time-dependent associations between iron and mortality in hemodialysis patients.  16:3070-3080. 2005
  • Towards a definition and classification of acute kidney injury.  16:3149-3150. 2005
  • Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage.  15:1244-1253. 2004
  • Glycosylation and Size of IgA1 Are Essential for Interaction with Mesangial Transferrin Receptor in IgA Nephropathy.  15:622-634. 2004
  • Comparison of Arteriovenous Grafts in the Thigh and Upper Extremities in Hemodialysis Patients.  14:2942-2947. 2003
  • Neuronal nitric oxide synthase: Its role and regulation in macula densa cells.  14:2475-2483. 2003
  • Racial differences in early-onset renal disease among young adults: The coronary artery risk development in young adults (CARDIA) study.  14:2352-2357. 2003
  • Impact of dialysis dose and membrane on infection-related hospitalization and death: Results of the HEMO study.  14:1863-1870. 2003
  • Gene delivery in renal tubular epithelial cells using recombinant adeno-associated viral vectors.  14:947-958. 2003
  • The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia.  13:2508-2516. 2002
  • Connective tissue growth factor (CTGF) N fragment: A marker for progressive diabetic nephropathy..  13:249A-249A. 2002
  • Role of P1P(2) and PIP3 in the regulation of ENaC by purinergic and corticoid receptors..  13:277A-277A. 2002
  • Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT1 receptors.  13:1131-1135. 2002
  • Purinergic receptor signaling at the basolateral membrane of macula densa cells.  13:1145-1151. 2002
  • Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome.  13:699-707. 2002
  • Hepatocyte growth factor alters renal epithelial cell susceptibility to uropathogenic Escherichia coli.  12:2543-2553. 2001
  • Manganese superoxide dismutase attenuates cisplatin-induced renal injury: Importance of superoxide.  12:2683-2690. 2001
  • Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus.  12:1630-1639. 2001
  • Impact of sodium and ultrafiltration profiling on hemodialysis-related symptoms.  12:151-156. 2001
  • Recommendations for the outpatient surveillance of renal transplant recipients.  11. 2000
  • Renal response to tissue injury: Lessons from heme oxygenase-1 gene ablation and expression.  11:965-973. 2000
  • Glycolate metabolism by Hep G2 cells.  10. 1999
  • Increased nitric oxide synthase-3 expression in kidneys of deoxycorticosterone acetate-salt hypertensive rats.  10:2283-2289. 1999
  • P2 purinoceptor saturation by adenosine triphosphate impairs renal autoregulation in dogs.  10:492-498. 1999
  • Angiotensin II stimulates macula densa basolateral sodium/hydrogen exchange via type 1 angiotensin II receptors.  10. 1999
  • Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.  10. 1999
  • Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.  10. 1999
  • Linoleyl hydroperoxide transcriptionally upregulates heme oxygenase-1 gene expression in human renal epithelial and aortic endothelial cells.  9:1990-1997. 1998
  • Losartan, an Angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.  9:1104-1108. 1998
  • Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994.  9:853-858. 1998
  • Differential activation of the Na:Ca exchanger by PMA in mesangial cells from salt sensitive hypertensive rats..  8:A1422-A1422. 1997
  • ET(A) receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat.  8:1054-1060. 1997
  • Agonist-induced calcium regulation in freshly isolated renal microvascular smooth muscle cells.  8:569-579. 1997
  • Temporal Induction of Clusterin in Cisplatin Nephrotoxicity.  8:302-305. 1997
  • Dominantly transmitted glomerulocystic kidney disease A distinct genetic entity.  8:77-84. 1997
  • Evaluation of pathologic criteria for acute renal allograft rejection: Reproducibility, sensitivity, and clinical correlation.  8:1930-1941. 1997
  • Expression of the amiloride-sensitive sodium channel β subunit gene in human B lymphocytes.  8:126-129. 1997
  • Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study.  7:831-835. 1996
  • Polymorphism in the beta subunit and Na+ transport.  7:2490-2494. 1996
  • Homocysteine and folate concentrations in blood from patients treated with hemodialysis.  7:2414-2418. 1996
  • The evaluation of living renal transplant donors: Clinical practice guidelines.  7:2288-2313. 1996
  • Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: Current concepts and management.  6:1160-1169. 1995
  • Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients.  5:1426-1433. 1995
  • Effects of dietary salt on angiotensin peptides in kidney.  6:1209-1215. 1995
  • Hyperkalemia in end-stage renal disease: Mechanisms and management.  6:1134-1142. 1995
  • The evaluation of renal transplant candidates: Clinical practice guidelines.  6:1-34. 1995
  • Translumbar inferior vena cava catheter for long-term hemodialysis.  5:2094-2097. 1995
  • GENE-EXPRESSION OF EPITHELIAL GLUCOSE TRANSPORTERS - THE ROLE OF DIABETES-MELLITUS.  5:S29-S36. 1994
  • Gene expression of epithelial glucose transporters: The role of diabetes mellitus.  5. 1994
  • Gene expression of epithelial glucose transporters: the role of diabetes mellitus..  5:S29-S36. 1994
  • Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients.  3:1570-1574. 1993
  • The kidney in sarcoidosis.  3:1555-1562. 1993
  • Effects of insulin and glucose on renal phosphate reabsorption: Interactions with dietary phosphate.  2:1593-1600. 1992
  • Influence of adenosine receptor blockade on renal function and renal autoregulation.  2:991-999. 1991
  • Renal sodium and water handling in hypothyroid patients: The role of renal insufficiency.  1:205-210. 1990
  • International Standard Serial Number (issn)

  • 1046-6673
  • Electronic International Standard Serial Number (eissn)

  • 1533-3450